Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder During the Phase 3 CHAMPION-NMOSD trial

              Author:Ortiz, Stephan   Pittock, Sean   Berthele, Achim   Levy, Michael   Nakashima, Ichiro   Oreja Guevara, Celia   Kim, Ho Jin   

              Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

              Topic:Autoimmune Neurology  

              Program Number:S5.004  

              Author Institution:Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Department of Neurology, Center MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Department of Neurology, School of Medicine, Technical University Munich, Munich, Germany, Munich, Germany  Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Tohoku University Graduate School of Medicine  Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Department of Neurology, National Cancer Center, Goyang, South Korea , Goyang, Korea, Republic of  

              Study design and methodology of the PREVAIL trial: a phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of subcutaneous ALXN1720 in adults with generalized myasthenia gravis

              Author:Howard, James   Rakhade, Sanjay   Scholz, Joachim   Ortiz, Stephan   Shang, Shulian   Vu, Tuan   

              Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

              Topic:Autoimmune Neurology  

              Program Number:P1.008  

              Author Institution:University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC  Alexion, AstraZeneca Rare Disease, Boston, MA  University of South Florida, Tampa, FL  

              Safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ALXN1720 in healthy volunteers: a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study

              Author:Ortiz, Stephan   McEneny, Alanna   Amancha, Praveen   Rice, Kara   Scholz, Joachim   Rakhade, Sanjay   Yee, Min   

              Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

              Topic:Autoimmune Neurology  

              Program Number:P1.016  

              Author Institution:Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA